Abstract
Background: Early recognition of duct-dependent congenital heart disease in newborns with duct-dependent pulmonary or systemic blood flow or transposition of the great arteries is critical for early introduction of prostaglandin E1 (PGE1), which allows stabilization of the newborn till cardiac catheterization or surgical intervention. Indications for PGE1, management of newborns with duct-dependent congenital heart disease and interventions in case of side effects of PGE1 are reviewed. Conclusions: It is critical to start with PGE1 infusion as soon as we clinically suspect ductdependent congenital heart disease. With this approach, morbidity and mortality of newborns with congenital heart disease is significantly reduced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
